# Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

> **NCT03552380** · PHASE2 · TERMINATED · sponsor: **Roberto Pili** · enrollment: 12 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03552380
- **Lead sponsor:** Roberto Pili
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-31
- **Primary completion:** 2022-06-07
- **Final completion:** 2024-02-15
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Funder halted development of compound in this disease
- **Last updated:** 2024-09-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03552380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03552380, "Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03552380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*